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The possible  participation  of the complement  (C) 1 system in  the pathogenesis  of 
various nervous disorders has been suggested in experimental animals and in man (1). 
Abnormal concentrations of C  components have been detected in cerebrospinal fluid 
(CSF)  from patients with systemic lupus erythematosus (2, 3) or degenerative neuro- 
logical diseases such as multiple sclerosis (4)  and subacute sclerosing panencephalitis 
(5).  These C  abnormalities  have not  always paralleled  changes of immunoglobulin 
(Ig) G  levels in CSF. It has been shown that liver DNA (6), myocardial mitochondria 
(7), certain lymphocytes, thymocytes (8), or killed kidney cells  (9)  can activate the C 
system  directly  without  the  participation  of  antibody.  These  reactions  may  be 
important  pathologically  in  the  induction  of secondary  nonspecific  inflammation 
after injury to these organs. 
The  present  study  was  undertaken  to examine  whether  nervous  tissues  can  also 
activate the C  system directly. Activation of C  following contact of sera with nervous 
tissue would provide a  mechanism for inflammatory changes in various neurological 
disorders. 
Materials  and Methods 
Experimental Animals.  Inbred BALB/e mice were obtained from Cumberland View Farms, 
Clinton, Tenn. Unless otherwise stated, 3-6-too-old healthy adult mice were used. New Zealand 
white rabbits weighing 3 kg were obtained from Dutchland Co., Denver, Pa. 
Sera.  Normal human sera  (NHS)  was obtained  from healthy laboratory personnel.  The 
presence or absence of C-reactive protein (CRP) was determined by immunoprecipitation (10). 
Agammaglobulinemic serum obtained  from a  patient  with X-linked  infantile  agammaglob- 
ulinemia used in our study contained <10/~g/ml IgG, no IgM, and no IgA. Rabbit blood was 
obtained by cardiac puncture; mouse blood was obtained by retro-orbital puncture. The blood 
was allowed to clot for 30 min at room temperature, and sera obtained by centrifugation and 
stored in aliquots at -70°C. 
Brain Homogenates.  Animals were killed  by cervical dislocation (mice) or by exsanguination 
(rabbits), and their brains were immediately removed and weighed. After washing in phosphate- 
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buffered  saline  (PBS),  pH  7.4, the  brains  were  homogenized  in  ice  with  a  Teflon-glass 
homogenizer (Talboys Engineering Corp., Emerson, N. J.) driven at 1500 rev/min. 
Material for  Complement Titrations.  Sheep erythrocytes were purchased  from the Colorado 
Serum Co.,  Denver, Colo.; sheep  hemolysin was  from BBL  Microbiology Systems,  Becton, 
Dickinson & Co., Cockeysville,  Md.; guinea pig C was from Texas Biological  Laboratories, Ft. 
Worth, Tex. 
Determination of Total Hemolytic C and C Components.  Glucose-gelatin-veronal-buffered  saline 
(pH 7.2) containing 1.0 mM Mg  ++ and 150 #M Ca  ++ (GGVB  ++) and gelatin-veronal-buffered 
saline (GVB) were prepared as described previously (11). Total hemolytic complement (TCH50) 
was determined by a modified method described previously (12) using IgM hemolysin-sensitized 
sheep  erythroeytes  (1  ×  l0  s  cells/ml). Titration of C  com  phonents (C1,  C4,  and  C2)  ~¢as 
performed using intermediate cells  EAC1 gp for  C4, EAClgP4 u for C2,  and EAC4  hu for C1. 
Functionally  pure C1 and C2 were prepared according to methods previously described (13). 
Guinea pig C diluted 1:25 in 0.04 M  EDTA was used as a source of C3-C9. The components 
C3-C7 were each titrated using EACI~4  hu and guinea pig or human C components obtained 
from Cordis Laboratories Inc., Miami, Fla. C8 and C9 were titrated using stable intermediate 
cells EACI~4-7  hu (Cordis Laboratories). 
EDTA in GVB (EDTA-GVB) and  10 mM EGTA containing 5 #M MgC1  (Mg++-EGTA- 
GVB) were used to deplete magnesium and or calcium ions, respectively. 
Protein Determinations.  Protein determinations were carried out according to the method of 
Lowry et al. (14). 
Consumptwn of C by Brain Homogenates.  Mouse or rabbit brain was dissected,  homogenized at 
4°C,  and the  protein concentration determined. Various dilutions in GVB  ++  of the brain 
homogenate were incubated with undiluted autologous serum or with normal human serum 
obtained from a healthy adult. The mixtures were incubated at 37°C for 30 min, centrifuged, 
and the residual C determined. The supernatants were also tested for C3 cleavage products by 
crossed  immunoelectrophoresis according to the method of Weeke (15) using 1% agarose in 
barbital buffer at pH 8.6 containing 10 mM EDTA. 
Preparation of Neuronal Cells, Glial Cells, and Myelin Fractions.  Whole fresh mouse brains were 
finely chopped with a razor blade and transferred into ice-cold 0.32 M sucrose,  10 mM Tris- 
HCI, pH 7.4. The minced tissue was then disrupted by passage  through nylon mesh, and the 
suspension was  sieved  through mesh of descending pore size down to 50/~m. All steps  were 
performed at 4°C. Neuronal cells, glial cells, and the myelin fraction were separated by the 
method of Blomstrand and Hamberger (16). The myelin enriched fraction was further purified 
by the procedure of Norton and Poduslo (I 7). 
Isolation of Myelin Basic protein.  Myelin basic protein (MBP) was extracted by either of the 
following methods. (a) This method was based on the procedure of Lira et al. (18) as modified 
by Golds and Braun (19). Briefly,  isolated myelin fragments that contained ~ 10 mg of MBP 
were partially delipidated by two extractions with 10 ml of cold acetone. The pellet containing 
MBP was recovered by centrifugation for  10 min at  10,000 g. MBP was solubilized from the 
pellet by the addition of 0.1 N HCI and stirring for 1 h at 4°C. The acid-insoluble  material was 
removed by centrifugation and MBP was precipitated from the supernatant by the addition of 
10 ml of cold acetone. The MBP precipitate was collected by centrifugation at  10,000 g for 20 
min at  -20°C and residual acetone removed by aspiration.  (b)  MBP was also solubilized 
directly from isolated myelin fragments without prior detipidation by stirring with 10% acetic 
acid containing 0.4 M NaCI for 4 h at 4°C. After centrifugation at  10,000 g the supernatant 
was dialyzed for 48 h against three changes of PBS. 
Cross-linking of Isolated MBP.  The cross-linked form of MBP was obtained by two methods. 
One method was done according to Golds and Braun (20) and the other was a modified method 
of Golds (personal communication). In the method described by Golds and Braun (20), 1 rag/ 
ml of MBP in PBS was incubated with 0.5 mg of difluorodinitrobenzene (DFDNB)  (Sigma 
Chemical Co., St. Louis, Mo.)  for 30 min at room temperature. The reaction was terminated 
by the addition of 3 vol of 1.0 M Tris-glycine, pH 9,0. After incubation for an additional 10 
min, the cross-linked myelin fragments were recovered by centrifugation at 10,000 g for 10 min, 
washed three times with water, and resuspended in PBS.  In the modified method  100 #g of 
purified MBP was reacted with 50/lg of DFDNB in 1 ml of acetone. The mixture was incubated CYONG,  WITKIN,  RIEGER,  BARBARESE,  GOOD,  AND  DAY  589 
at room temperature for 30 rain, and the reaction was terminated by the addition of 300/~l of 
1 M glycine-Tris pH 9. After incubation for an additional 10 min,  1 ml of 50% trichloroacetic 
acid  (TCA) was added and the mixture  was left on ice for  15 min.  After centrifugation  the 
mixture  was  reacted  with  1 ml  of ether:ethanol  (3:2) mixture  at  -20°C  for  10  rain  and 
centrifuged.  This latter  procedure  was repeated  three times, and the residual  protein,  treated 
with ether  (-20°C) for 10 min, was resuspended in PBS to its original concentration. 
Results 
Consumption of C by  Brain Homogenates from  Adult  Rabbit, Adult  Mouse, and Newborn 
Mouse.  Fig.  1 presents the consumption of C after incubation of different concentra- 
tions  of either  mouse  brain  homogenate with  NHS,  or  different  concentration  of 
rabbit  brain  homogenates with  normal  rabbit  serum  or NHS.  As shown,  the  con- 
sumption of C by both homogenates was dose dependent. The degree of C  depletion 
by rabbit  brain  homogenate was  higher  using  rabbit  serum.  6  mg protein/ml  of 
mouse  brain  homogenate also  reduced  total  hemolytic C  by  37%  in  sera  from  a 
patient with agammaglobulinemia (<10/~g/ml IgG/ml) (data not shown). 
To determine the time of appearance of the anticomplementary activity in mouse 
brain,  homogenates of brain  (6  mg/ml)  of BALB/c  mice  at  different  ages  were 
incubated with NHS. As shown in Fig. 2, brain homogenates of newborn mice did 
not consume C. The anticomplementary activity first  appeared  7 d  after birth  and 
thereafter  increased  dramatically with  age.  Brain  homogenates of newborn rabbits 
were not studied. 
Kinetics and Temperature Dependence of C Activation by Brain Homogenates.  Brain  ho- 
mogenates (6 mg protein/ml) of adult rabbits or mice were incubated with NHS and 
aliquots were removed at timed intervals and assayed for residual TCH50. As shown 
in  Fig.  3,  a  maximum decrease  of TCH50 occurred 30  min  after  incubation  with 
either the mouse or rabbit brain homogenate. The consumption of TCH50 by 6 mg/ 
ml  of either  mouse  or  rabbit  brain  homogenate was  also  temperature  dependent 
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Fie.  1.  Concentration-dependent depletion of TCH50 by brain homogenates. Different concen- 
trations  of BALB/c  mouse brain  homogenates ((D) were  incubated  with  NHS,  or  rabbit  brain 
homogenates were incubated with NHS (A) or autologous serum (V) at 32°C for 30 rain. Residual 
TCH50 was then determined. 590  COMPLEMENT  ACTIVATION BY  MYELIN 
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FIO.  2.  Age-related appearance of anticomplementary activity in murine brains. Brain homoge- 
nates from BALB/c mice at various ages (12 mg/ml) were incubated with equal volumes of NHS 
at 37°C for 30 min, and residual TCH50 was determined. 
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FIo. 3.  Time-dependent depletion of TCH50 by brain homogenates. Brain homogenates (6 mg/ 
ml in GVB  ++) from BALB/c mice (O) and rabbit (l~) were incubated with equal volumes of NHS 
at 37°C for various times, and residual TCH50 was determined. 
(Fig. 4), and no significant differences were observed in the reactivity between the 
two homogenates at any temperature. 
Physical Properties of Brain Homogenates.  Mouse or rabbit brain homogenates were 
incubated at 50°C or 56°C for 30 rain and then reacted with NHS. Controls consisted 
of NHS  incubated with  GVB  ++.  In  another experiment, brain homogenates were 
subjected to freezing and thawing three or five times before testing for anticomple- 
mentary activity. Table I shows that the anticomplementary activity was heat labile 
at 56°C for 30 min, and that freezing and thawing 5 times reduced the anticomple- 
mentary activity of mouse and rabbit brain homogenate by 26 and 9%, respectively, 
of the control. 
Consumption of Human C Components and Cleavage of Human C3 by Mouse Brain Homoge- CYONG,  WITKIN, RIEGER,  BARBARESE, GOOD,  AND DAY  591 
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Fro. 4.  Temperature-dependent depletion  of TCH50  by brain homogenates. BALB/c ~  and 
rabbit ~  brain homogenates (6 mg/ml) were incubated with equal volumes of NHS for 30 rain at 
various temperatures, and residual TCH50 was determined. 
TABLE  I 
Effect of Temperature and Freezing and Thawing on Complement Depletion by 
Mouse and Rabbit Brain Homogenates 
Pretreatment* 
Decrease in antieomple- 
mentary activity~ 
Mouse  Rabbit 
%  % 
50°C 30 rain  69  19 
56°(3 30 min  96  80 
Freezing and thawing three times  5  0 
five times  26  9 
* Mouse and rabbit brain homogenate were treated as described, NHS added, 
and the mixtures incubated at 37°C for 30 rain. 
:[: Activities were compared with the TGH50 of NHS incubated with GVB ÷* 
under identical conditions. 
nares.  Fig.  5  presents  levels of residual  C  components  in  human  serum  following 
incubation  with  mouse  brain  homogenates  (12  mg/ml).  As  shown,  each  of  the 
components from C1-C7 was markedly decreased. The later components 128 and 129 
did not change as much as the earlier components. 
C3 tested by crossed-immunoelectrophoresis showed a  dramatic cleavage of C3 to 
C3d following incubation of NHS with  12 mg/ml brain homogenate (Fig. 6, panel A) 
when compared with C3 of NHS incubated with GVB ++ for the same period of time 
(panel C). When the concentration of mouse brain homogenate was reduced to 6 mg/ 
ml and incubated with NHS, native C3 as well as a C3b peak was observed (panel B). 
Effect  of  Ca ++  and  Mg +÷  on  Activation  of Human  C3  by  Mouse  and  Rabbit  Brain 
Homogenates.  The requirements of Ca  ++ and Mg  ++ for activation of human C3 were 
studied next because C  activation by the classical pathway requires Ca  +`` and Mg  ++, 
and  the  alternative  pathway  is  strongly  influenced  by  Mg  *+  alone.  Serum  was 
chelated  with  10  mM  EGTA  to  bind  Ca ++  and  to  prevent  classical  C  pathway 
activation, and then supplemented with 1 mM Mg  +÷ to allow for alternative pathway 
activation. Brain homogenates incubated with unchetated serum  (Table II) strongly 592  COMPLEMENT  ACTIVATION  BY  MYELIN 
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Fie_,.  5.  Hemolytic  complement  component  titers  after  incubation  with  BALB/c  mice  brain 
homogenates. Brain  homogenates (12  mg/ml in GVB  ++)  were  incubated with equal  volumes of 
NHS at 37°C for 30 min (tin) or for 60 rain (t2) and functional C  assays were performed. 
activated C3 (89% using mouse brain and 100% using rabbit brain). No C3 activation 
occurred, however, when the same homogenates were incubated with NHS containing 
either Mg+÷-EGTA or EDTA (Table II). This result indicates that the activation of 
C3 by brain homogenate occurs via the classical pathway. 
Location of AnticomplementaTy Activity  in Brain Tissue.  Whole brain was separated into 
myelin, glial cell (astrocytes, oligodendrocytes, and microglia), neuronal cell, and cell 
nuclei fractions. After homogenization and adjustment to equal protein concentrations 
(1 mg/ml), the ability of each fraction to activate C in NHS was compared. As shown 
in  Fig.  7,  the  summarized  data  of eight  independent  experiments,  >70%  of the 
anticomplementary  activity  was  recovered in  the  myelin  fraction;  no  significant 
anticomplementary activity was observed with the other fractions. 
Anticomplementa~y Activity  of MBP.  The myelin fraction described above still con- 
tained several components.  Murine  myelin was  further purified by the  method of 
Norton and Poduslo (17).  Approximately a  third of the anticomplementary activity 
was  still retained. The isolated murine  myelin was  then purified to obtain  myelin 
basic proteins by two procedures. One procedure eliminates lipid components during 
isolation  (19).  The other technique does not involve the use of any organic solvent 
during isolation (19). The fractions of purified myelin, MBP, free myelin, and cross- 
linked MBP were brought up to  1 mg protein. MBP extracted by either of the two 
methods showed almost no anticomplementary activity (<5% reduction in TCH50). 
However, the  myelin  residues  remaining  after MBP  extraction  also  possessed  no 
anticomplementary activity (<3% reduction in TCH50). These results are shown in 
Fig. 8. 
MBP,  however,  exists  in  nervous  tissue  as  a  dimer  while  extracted  MBP  is  a 
monomer (19).  Purified MBP was therefore dimerized with DFDNB and reassayed 
for anticomplementary activity. After polymerization, MBP was now anticomplemen- 
tary  (Fig.  8)  and  the specific activity per mg protein  was  higher than  in  purified 
myelin.  Polymerized  MBP-free  myelin  and  DFDNB  used  as  controls  were  not 
anticomplementary (data not shown). Fractionated 3-d-old mouse brain (myelin and 
cellular fractions) also exhibited no ability to activate C  (data not shown). 
In addition to the above experiments we used murine (C57B1/6) MBP purified by CYONG,  WITKIN,  RIEGER,  BARBARESE,  GOOD,  AND  DAY  593 
Fic.  6.  C3  activation  by BALB/c mice brain  homogenate. NHS was incubated with  an equal 
volume of (A)  12 mg/ml or (B) 6 mg/ml brain homogenates or with GVB  ++ (C) for 30 min at 37°C. 
The sera were then subjected to cross immunoelectrophoresis to locate C3 cleavage products. The 
anode is to the left. 
Dr.  E.  Barbarese.  Dr.  Barbarese  has  identified four proteins  that  are antigenically 
related to the myelin basic protein designated prelarge (mol wt 21,500), large (18,500), 
presmall  (17,000), and small  (14,000)  (21). We tested a  mixture of 14K and  18.5K 
MBP.  The purity of the two proteins we used is shown  in  Fig.  9.  As presented in 
Table III,  the  purified  MBP  (14K and  18.5K)  was  not  anticomplementary.  After 
dimerization according to the modified method of Golds (personal communication), 
complement was activated by >95%. 
Discussion 
Myelination of the postnatal murine central nervous system occurs in at least two 
stages  (22). The first stage, at 8-15  d  of age, involves the proliferation of oligoden- 
droglial cells. During the second stage, at  16-25 d  of age, histologically recognizable 594  COMPLEMENT  ACTIVATION  BY  MYELIN 
TAnL~  II 
Effect of Calcium and Magnesium Ion on C3 Depletion by Mouse and Rabbit Brain Homogenates 
Mode of action  Percent re- 
Brain source  Buffer  C3 titer after  duction of 
Classi-  Alter-  incubation  C3 activity  cal  native 
BALB/c  Diluted GVB  +÷  +  +  260  88 
Mg-EGTA  -  +  3812  5 
EDTA  -  -  3742  6 
Rabbit  GVB  ++  +  +  0  100 
Mg EGTA  -  +  3659  5 
EDTA  -  -  4583  5 
Buffer alone  GVB  ÷+  +  +  2173 
Mg-EGTA  -  +  3600 
EDTA  -  -  3936 
i 
NHS  diluted  1:3  by  GVB  ÷÷,  Mg+÷-EGTA,  or  EDTA  was  incubated  with  6  mg  protein/ml  brain 
homogenate at 37°C for 30 rain. 
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myelin can be observed (17). Our  data  clearly indicate that  the ability of the murine 
brain to activate complement  very closely parallels the pattern  of myelination. 
Brain homogenates  from both mouse and rabbit were shown to possess anticomple- 
mentary  activity.  Following brain  fractionation, the activity was localized  in myelin. 
It  was  further  demonstrated  that  polymerized  MBP  but  not  monomeric  MBP  was 
anticomplementary.  Dimerization  of MBP  by the  DNDFB  method  has been  exten- 
sively studied  by Golds and  Braun  (20).  The  reaction  depends  on  the concentration 
of both  the  reagent  and  protein.  In  addition  to  reaction  with  amino  groups  on  the 
protein, the reagent can react with sulfhydryl imidizole tyrosine-hydroxyl groups, but 
only the amino  group  modification  is stable. By the above method,  20% of the MBP 
FIG.  7.  Localization of anticomplementary activity in murine brain tissue.  Whole BALB/c mice 
brain homogenates were fractionated on a sucrose-ficoll  discontinuous gradient, and each fraction 
was assayed for anticomplementary activity. The percentage of total anticomplementary activity in 
each fraction is plotted on the graph. CYONG,  WITKIN,  RIEGER,  BARBARESE,  GOOD,  AND  DAY 
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FIo.  8.  Anticomplementary activity of myelin and MBP. The ability of purified myelin, purified 
myelin basic protein, residues of myelin after extraction of MBP, and cross-linked myelin basic 
protein to reduce the TCH50 of NHS was determined. 
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Fie.  9.  Sodium dodecy! sulfate-polyacrylamide gel of murine MBP (I4K and 18.5K). 596  COMPLEMENT  ACTIVATION  BY  MYELIN 
TABLE  III 
Consumption of Total Hemolytic Complement Using Purified Murine MBP 
Total hemolytic C 
CH50 U/ml 
NHS  43 
MBP monomer (18.5K and 14K)  46 
MBP cross linked  5 
MBP (50/~g in 50/zl PBS) was reacted with 50/~1 of 1:5 dilution of NHS at 
37°C  for  30  min,  and  the  residual  TCH50  was  then  tested.  Control  NHS 
treated under identical conditions contained 50/~1 of PBS. 
is  dimerized and  small  amounts  of higher heteropolymers are  also  produced  (20). 
Whether it is the MBP dimer per se or other alterations of the MBP produced by 
DNDFB that account for the activation of the C system by treated MBP will have to 
be answered by subsequent experiments. 
Siegel  et  al.  (23)  have  reported  that  isolated,  naturally  occurring  polycations 
including  MBP  activate  C  only in  the  presence of (3RP.  The  sera  we  tested  for 
activation  of (3  did  not  have  demonstrable  CRP  by  the  method  used.  However, 
because small amounts of CRP are present in normal blood, participation by (3RP in 
the activation of C  by myelin cannot be absolutely excluded. It seems possible that 
CRP may polymerize MBP or change its conformation so that it can readily activate 
the C system. 
Current hypotheses concerning the pathogenesis of postinfectious and postvaccinal 
disorders of the nervous system focus on the role of the cellular immune system (24). 
Such hypotheses have developed largely as a result of  the clinical and histopathological 
similarities between these human disorders and experimental allergic neuritis (EAN) 
and experimental allergic encephalomyelitis (EAE) in laboratory animals. Both EAN 
and EAE appear to result from delayed hypersensitivity to MBP. In addition, both 
EAE and  EAN follow sensitization with nervous system antigen in the presence of 
Freund's  complete adjuvant  but  not  in  the  presence of incomplete adjuvant.  The 
mechanism  whereby a  wide variety of infections, immunizations,  and  vaccinations 
induce similar sensitization to MBP has not, to date, been satisfactorily explained. 
The histopathological features of postinfectious diseases of the nervous system have 
been recently reviewed (24).  It was postulated that perivascular demyelination may 
also  result  from  vascular  injury  alone,  in  the  absence  of delayed hypersensitivity 
reactions. The recent detection of antigen-antibody complexes circulating in the sera 
of patients  with  a  variety of neurological  disorders  (25,  26)  suggests  a  pathologic 
mechanism  whereby the complexes induce a  primary vascular lesion that,  in turn, 
leads  to  demyelination.  The  present  study  suggests  that  neuronal  tissue  necrosis 
resulting in the exposure and/or release of MBP can lead to activation of the (2 system 
in the absence of autoantibodies. Since MBP is detected in sera and cerebral spinal 
fluids  after brain  injury  (27)  and  in  patients  with  multiple  sclerosis  (28),  such  C 
activation may be responsible, at least in part, for the development of acute inflam- 
mation, magnification of the damaged area, and the occurrence of vascular spasms 
following brain hemorrhage. 
Summary 
Murine or rabbit whole brain homogenates were shown to activate human comple- 
ment  via the classical pathway by an antibody-independent reaction. This activity CYONG, WITKIN, RIEGER, BARBARESE, GOOD, AND DAY  597 
required  Ca  ~:+ ions.  Anticomplementary activity in  fractionated  murine  brain  was 
found to reside in the myelin fraction and in purified myelin. It was absent, however, 
both  from  highly  purified  myelin  basic  protein  (MBP)  and  from  the  MBP-free 
residue.  Because purified MBP is a  monomer and this protein exists in brain tissue 
largely as a dimer, the ability of the cross-linked form of MBP to activate complement 
was investigated. MBP, dimerized with difluorodinitrobenzene, was highly anticom- 
plementary. The murine brain,  inactive when taken  from the newborn mouse, was 
shown to first  acquire the capacity to activate complement at  7 d  after birth.  This 
finding is consistent with  the  report  that  the synthesis of myelin protein  has  been 
shown  to  be  initiated  in  murine  brain  8  d  after  birth.  Complement  activation by 
MBP could play an important role in the pathological changes observed in neurolog- 
ical disorders. 
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